Positron emission tomography/computed tomography in melanoma

Austin Bourgeois, Ted T. Chang, Lindsay M. Fish, Yong Bradley

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) has been invaluable in the assessment of melanoma throughout the course of the disease. As with any modality, the studies are incomplete and more information will be gleaned as our experience progresses. Additionally, it is hoped that a newer PET agent in the pipeline will give us even greater success in the identification and subsequent treatment of melanoma. This article aims to examine the utilization of PET/CT in the staging, prognostication, and follow-up of melanoma while providing the physicians who order and interpret these studies practical guidelines and interpretive pitfalls.

Original languageEnglish (US)
Pages (from-to)865-879
Number of pages15
JournalRadiologic Clinics of North America
Volume51
Issue number5
DOIs
StatePublished - Sep 1 2013

Fingerprint

Melanoma
Fluorodeoxyglucose F18
Guidelines
Physicians
Positron Emission Tomography Computed Tomography
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Positron emission tomography/computed tomography in melanoma. / Bourgeois, Austin; Chang, Ted T.; Fish, Lindsay M.; Bradley, Yong.

In: Radiologic Clinics of North America, Vol. 51, No. 5, 01.09.2013, p. 865-879.

Research output: Contribution to journalReview article

Bourgeois, Austin ; Chang, Ted T. ; Fish, Lindsay M. ; Bradley, Yong. / Positron emission tomography/computed tomography in melanoma. In: Radiologic Clinics of North America. 2013 ; Vol. 51, No. 5. pp. 865-879.
@article{095d4c94c96941578d0513a55201433b,
title = "Positron emission tomography/computed tomography in melanoma",
abstract = "Fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) has been invaluable in the assessment of melanoma throughout the course of the disease. As with any modality, the studies are incomplete and more information will be gleaned as our experience progresses. Additionally, it is hoped that a newer PET agent in the pipeline will give us even greater success in the identification and subsequent treatment of melanoma. This article aims to examine the utilization of PET/CT in the staging, prognostication, and follow-up of melanoma while providing the physicians who order and interpret these studies practical guidelines and interpretive pitfalls.",
author = "Austin Bourgeois and Chang, {Ted T.} and Fish, {Lindsay M.} and Yong Bradley",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.rcl.2013.06.004",
language = "English (US)",
volume = "51",
pages = "865--879",
journal = "Radiologic Clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Positron emission tomography/computed tomography in melanoma

AU - Bourgeois, Austin

AU - Chang, Ted T.

AU - Fish, Lindsay M.

AU - Bradley, Yong

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) has been invaluable in the assessment of melanoma throughout the course of the disease. As with any modality, the studies are incomplete and more information will be gleaned as our experience progresses. Additionally, it is hoped that a newer PET agent in the pipeline will give us even greater success in the identification and subsequent treatment of melanoma. This article aims to examine the utilization of PET/CT in the staging, prognostication, and follow-up of melanoma while providing the physicians who order and interpret these studies practical guidelines and interpretive pitfalls.

AB - Fludeoxyglucose F 18 positron emission tomography/computed tomography (PET/CT) has been invaluable in the assessment of melanoma throughout the course of the disease. As with any modality, the studies are incomplete and more information will be gleaned as our experience progresses. Additionally, it is hoped that a newer PET agent in the pipeline will give us even greater success in the identification and subsequent treatment of melanoma. This article aims to examine the utilization of PET/CT in the staging, prognostication, and follow-up of melanoma while providing the physicians who order and interpret these studies practical guidelines and interpretive pitfalls.

UR - http://www.scopus.com/inward/record.url?scp=84883439937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883439937&partnerID=8YFLogxK

U2 - 10.1016/j.rcl.2013.06.004

DO - 10.1016/j.rcl.2013.06.004

M3 - Review article

VL - 51

SP - 865

EP - 879

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

SN - 0033-8389

IS - 5

ER -